Nano Publications Nano Publications

01.

Publications

Nanobiotix est une entreprise pionnière en nanomédecine depuis plus de 10 ans. L’idée est de développer une approche innovante, différente des approches classiques des sociétés pharmaceutiques ou biotechnologiques : une nouvelle façon de traiter les patients grâce à la nanophysique appliquée au cœur de la cellule.

Au fil des ans, de nombreuses publications et abstracts ont été publiés dont une partie importante a été réunie dans cette bibliographie en ligne de Nanobiotix.

01. Données cliniques de NBTXR3

Les publications de cette section regroupent les résultats des essais cliniques avec NBTXR3. Ces rapports ont été publiés dans des revues scientifiques de premier plan après examen par un comité de lecture.

L’examen par un comité de lecture signifie que le rapport a été examiné par un ou plusieurs experts ayant des compétences dans le domaine en question, avant d’être accepté pour publication par la revue.

  • Tout
  • Tête & Cou
  • Foie
  • Poumon
  • Pancréas
  • Rectum
  • STM

2022 – NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma

2022 – Nanoparticle therapy for head and neck cancers

2021 – Eur J Surg Oncol – STS Retrospective Study

2021 – Eur J Cancer – NBTXR3 Phase I in HNSCC

2019 – The Lancet Oncology – Act.In.Sarc

2016 – Phase I data NBTXR3 Soft Tissue Sarcoma – Bonvalot et al.

2014 – Metals as Nanosized Radioenhancers – Pottier et al.

02. Données précliniques (études in vitro et in vivo) de NBTXR3

Les publications de cette section incluent les données in vitro et in vivo de NBTXR3. In vitro signifie que le produit NBTXR3 a été étudié dans des cellules en dehors de leur contexte biologique habituel.

In vivo signifie que NBTXR3 a été testé sur des animaux. Ces rapports ont été publiés dans des revues scientifiques de premier plan après examen par un comité de lecture (pour la définition, se reporter à la partie ci-dessus relative aux données cliniques).

  • Tout
  • In Vitro
  • In Vivo

2021 – A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model

2021 – Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects

2021 – NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models

2020 – Endobronchial ultrasound-guided injection of NBTXR3 radio-enhancing nanoparticles into mediastinal and hilar lymph nodes: a swine model to evaluate feasibility, injection technique, safety, nanoparticle retention and dispersion

2020 – Int J Nanomedicine NBTXR3 Induces Abscopal Effect

2019 – Radiother Oncol – NBTXR3 improves cGAS-STING activation

2014 – NBTXR3 concept and dose enhancement – Marill et al.

2012 – Efficacy of NBTXR3 in vitro and in vivo – Maggiorella et al.

03. Divers

Dans cette section sont regroupées les publications relatives à d’autres technologies de Nanobiotix ou à des sujets de recherche spécifiques.

2019 – Bulletin Cancer – NBTXR3 improves pathological response

2017 – Nano-sized cytochrome p450 3a4 inhibitors to block hepatic – Paolini et al.

2017 – A new opportunity for nanomedicines – Paolini et al.

2015 – Metals as radio-enhancers in oncology – Pottier et al.

2015 – The future of nanosized radiation enhancers – Pottier et al.

2010 – Nanocarrier for Photodynamic Therapy – Thienot et al.

2010 – Silica Nanoparticles – Simon et al.

2010 – Combinations of proteins with Nano-Systems – Di Marco et al.

02.

Abstracts

Les congrès sont clés pour Nanobiotix, lors de ces évènements, la Société publie des données et des résultats scientifiques. Cette section répertorie les abstracts qui ont été acceptés et publiés par Nanobiotix au cours de la dernière décennie.

Laurent Levy au S3 Odéon

01. Données cliniques de NBTXR3

Les abstracts de cette section concernent les résultats des essais cliniques menés avec NBTXR3.

  • Tout
  • Tête & Cou
  • Foie
  • Poumon
  • Pancréas
  • Rectum
  • STM

2021 – A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients

2021 – Study of Novel Radioenhancer NBTXR3 Plus Radiotherapy in Patients With Locally Advanced Soft Tissue Sarcoma: Results of the Long-Term Evaluation in the Phase II/III Act.In.Sarc Trial

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

2021 – Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

2021 – NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in patients with advanced cancers: phase I trial

2021 – Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients

2021 – Long-term results from the phase II/III Act.In.Sarc trial evaluating NBTXR3 in locally advanced STS

2021 – Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/III Act.In.Sarc trial

2021 – NBTXR3 activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

2021 – Radiation enhancing NBTXR3 for the treatment of cisplatin-ineligible locally advanced HNSCC patients

2021 – Results from the phase I dose-escalation study of the radiation enhancer NBTXR3 for the treatment of HCC and liver metastases

2021 – A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial

2020 – Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers

2020 – RT-activated hafnium oxide nanoparticles in cisplatin-ineligible locally advanced HNSCC patients

2020 – NANORAY-103: Phase I/II trial of NBTXR3 activated by SBRT in patients with HCC and liver metastases

2020 – Phase I/II Study Of Radiation Enhancing Hafnium Oxide Nanoparticles NBTXR3 Activated by SBRT in HCC and Liver Metastases Patients

2020 – NBTXR3 radiation enhancing hafnium oxide nanoparticles: RP2D for the treatment of HCC and liver metastases

2020 – NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Cisplatin-Ineligible Patients With Locally Advanced HNSCC: A Phase I Trial

2020 – Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy

2020 – Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

2020 – Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study

2020 – Treatment of hepatocellular carcinoma and liver metastases with hafnium oxide nanoparticles activated by SBRT: a phase I/II trial

2020 – ESTRO – NBTXR3 for the Treatment of Advanced Liver Cancers

2020 – SITC – NBTXR3 with Anti-PD-1 Therapy

2020 – ESTRO – NBTXR3 for the Treatment of Locally Advanced HNSCC

2020 – ASTRO – NBTXR3 in HNSCC

2020 – ASTRO – NBTXR3 in Advanced Liver Cancers

2020 – ASTRO – NBTXR3 in Combination with Anti-PD-1

2020 – ESMO – NBTXR3 in HCC and Liver Metastases

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

2020 – MHNCS – NBTXR3 for locally advanced HNSCC

2020 – ASCO-SITC – NBTXR3 with anti-PD-1 therapy

2020 – ASCO GI – Treatment of liver cancers with NBTXR3

2019 – A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With an Anti-PD-1 Therapy

2019 – NBTXR3 for the treatment of locally advanced HNSCC in frail and/or elderly patients: a phase I/II study

2019 – Phase I study of hafnium oxide nanoparticles activated by Intensity Modulated Radiation Therapy (IMRT) as a new therapeutic option for elderly or frail HNSCC patients

2019 – Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis

2019 – Hafnium oxide nanoparticles activated by SBRT for the treatment of hepatocellular carcinoma and liver metastasis: a phase I/II trial

2019 – ESMO IO – NBTXR3 with anti-PD-1

2019 – RSNA – Treatment of locally advanced HNSCC by NBTXR3

2019 – SIOG – NBTXR3 for the treatment of elderly/frail HNSCC patients

2019 CTOS NBTXR3 in STS phase II/III trial

2019 – ESMO – NBTXR3 activated by SBRT in liver cancers

2019 – ASTRO – NBTXR3 for the treatment liver cancers

2019 – ASTRO – NBTXR3 for the treatment of solid tumors

2019 – ESMO WGI – NBTXR3 in unresectable liver cancers

2019 – ASCO – NBTXR3 in Liver Cancers

2019 – ASCO – Phase I NBTXR3 in elderly/frail HNSCC patients

2019 – AHNS – Phase I/II NBTXR3 in combination with anti-PD-1

2019 – ESTRO – Randomized NBTXR3 trial in STS

2019 – ESTRO – NBTXR3 activated by SBRT in liver cancers

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

2019 – ASCO GI – Phase I/II NBTXR3 in HCC and Liver Metastasis

2018 – ASTRO – NBTXR3 Anti-Tumor Immune Response

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

2018 – SIOG – NBTXR3 In Elderly With HNSCC

2018 – ASTRO – NBTXR3 Exploratory Dosimetric Study

2018 – ASTRO – NBTXR3 in solid tumors

2018 – ESMO – Phase II/III NBTXR3 in STS

2018 – ASTRO 2018 – NBTXR3 in elderly HNSCC

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

2018-ASTRO 2018- NBTXR3 in liver cancers

2018 – ESMO – NBTXR3 in HCC and Liver Metastasis

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

2017 – Abstract SITC Conference Maryland – Clinical

2017 – A phase 1 trial of NBTXR3 nanoparticles activated by IMRT in the treatment of advanced-stage head and neck carcinoma

2017 – Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients

2014 – ASCO Abstract – Preliminary Data NBTXR3 Soft Tissue Sarcoma – Bonvalot et al.

02. Données précliniques (études in vitro et in vivo) de NBTXR3

Les abstracts de cette section présentent des données in vitro et in vivo de NBTXR3.

In vitro signifie que le produit NBTXR3 a été étudié dans des cellules en dehors de leur contexte biologique habituel. In vivo fait référence aux tests menés avec NBTXR3 sur des animaux.

  • Tout
  • In Vitro
  • In Vivo

2021 – Radiotherapy-activated NBTXR3 nanoparticles Increase CD8+ T cell infiltration and diversity in tumors, and modulate the immunopeptidome of cancer cells

2021 – Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice

2021 – Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside

2020 – NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model

2020 – SITC – NBTXR3 Generates Long Term Immune Memory

2020 – SITC – TCR Repertoire

2019 – NBTXR3 Activated By Radiotherapy Generates an Anti-Tumor Immune Response

2019 – RSNA – Anti-tumor immune response induced by NBTXR3

2019 – ASTRO – NBTXR3 generates an anti tumor immune response

2019 – ASCO – NBTXR3 induces antitumor immune response

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

2018 – OncoRad – NBXTR3 Abscopal Effect

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

2017 – Abstract SITC Conference Maryland – Non Clinical

2017 – Abstract AACR-EORTC-NCI

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

2017 – Immunotherapy Workshop

2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro

2017 – AACR Abstract – NBTXR3 anti-tumor efficacy in vivo

2016 – SITC Abstract – NBTXR3 for in situ cancer vaccination

2011 – ECCO Abstract – NBTXR3 as promising cancer therapy – Magiorella et al.

2011 – AACR Abstract – NBTXR3 radioenhancement and anti-tumor effect in vitro – Magiorella et al.

2010 – ESTRO Abstract – hafnium Oxide nanoparticles as anti cancer agent – Deutsch et al.

03. Divers

Dans cette section sont regroupés les abstracts relatifs à d’autres technologies de Nanobiotix ou à des sujets de recherche spécifique.

2017 – AACR-EORTC-NCI Monte Carlo Calculation

2015 – Clinical Sciences and Drug Discovery Abstract – Use of metals as nano-sized radiation enhancers – Pottier et al.

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

2010 – CLINAM Abstract – Expected and Unexpected Side Effects of Nanodrugs – Levy et al.

2010 – GDR Photomed Abstract – Silica Nanoparticles for Photodynamic Therapy – Thienot et al.

BESOIN DE PLUS D’INFORMATIONS?

Si vous avez une question, n’hésitez pas à nous contacter

Contactez-nous
25
PUBLICATIONS
112
ABSTRACTS
143
ILLUSTRATIONS
233
AUTEURS